IPP Bureau
Ascletis Pharma completes patient enrollment in clinical for cure of HIV infection
By IPP Bureau - September 16, 2022
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
Cytel unlocks innovative clinical development expertise for APAC biopharma sector
By IPP Bureau - September 15, 2022
Cytel has now established entities in Australia, Shanghai, Beijing, and Singapore, and plans to expand into Seoul and Tokyo in the coming years.
Zydus receives final approval from USFDA for Lenalidomide Capsules
By IPP Bureau - September 15, 2022
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
NMDP focuses on smooth transition to licensing of Class-A and B medical devices
By IPP Bureau - September 15, 2022
The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017
AstraZeneca launches up-skilling program iPHARMACY
By IPP Bureau - September 15, 2022
The company has partnered with Neethi, a Kerala state cooperative consumers federation limited company, to run this program in Kerala
Dr. Jaidev Rajpal appointed MD & CEO of Jubilant Generics
By IPP Bureau - September 15, 2022
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Zydus receives final approval from USFDA for Cariprazine Capsules
By IPP Bureau - September 15, 2022
Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder
Alkem Laboratories appoints Srinivas Singh as Executive Director
By IPP Bureau - September 15, 2022
He holds a Bachelor’s Degree in Science and has joined the company in 2012 and has over 10 years of experience in pharmaceutical industry
Lupin receives Health Canada approval for Rymti
By IPP Bureau - September 14, 2022
Rymti is indicated in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis, plaque psoriasis, and paediatric plaque psoriasis
Mandaviya launches NLEM 2022
By IPP Bureau - September 14, 2022
This will give a boost to cost-effective, quality medicines and contribute towards reduction in out of pocket expenditure on healthcare for the citizens
ProBioGen receives Employer of the Future and the Top Service awards
By IPP Bureau - September 14, 2022
They also noted ProBioGen's digitalization investments and strategy, as well as its support for its employees.
Philips Foundation and RAD-AID International embark on a multi-year cross-continental partnership
By IPP Bureau - September 14, 2022
Philips Foundation and RAD-AID International leverage Philips’ expertise in mobile ultrasound services to improve access to virtual care in hard-to-reach areas
Takara Bio partners with BioeXsen for the distribution of CE-IVD solutions
By IPP Bureau - September 14, 2022
The reliability of their products, evidenced by their inclusion in the WHO emergency use list, has further improved with the addition of Takara Bio's enzymes.
Medvarsity partners Wolters Kluwer to improve learning outcomes
By IPP Bureau - September 13, 2022
This association between the two esteemed organizations allows Medvarsity to significantly – and positively – impact healthcare education
Tata Memorial Centre suggests low-cost intervention for breast cancer
By IPP Bureau - September 13, 2022
If implemented across the world, it has the capability to save over 100,000 lives annually
